Objective: Improved means to monitor and guide interventions could be useful in the intensive care unit. Metabolomic analysis with bioinformatics is used to understand mechanisms and identify biomarkers of disease development and progression. This pilot study evaluated plasma proton nuclear magnetic resonance spectroscopy as a means to monitor metabolism following albumin administration in acute lung injury patients.
A cute lung injury (ALI) and its more severe counterpart, acute respiratory distress syndrome, are among the most common conditions encountered in the intensive care unit (ICU) (1, 2) . In patients with sepsis, hypoproteinemia is a predictor of the development of ALI and subsequent clinical outcomes, including elevated hydrostatic pressures, fluid retention, and weight gain, which are associated with mortality (3, 4) . Fluid restrictive strategies and diuretics (e.g., furosemide) are effective in reducing the duration of mechanical ventilation (5) , and the addition of albumin to furosemide therapy in hypoproteinemic patients with ALI significantly improves oxygenation, net fluid balance, and hemodynamic stability (6, 7) . However, therapeutic responses are not uniform, and the mechanisms underlying any benefit remain unknown (8) . Additional means to predict responses, monitor status, and improve outcomes are needed.
Metabolic profiling methods could be useful in the ICU by providing means to identify and quantify metabolomic characteristics in plasma to guide clinical care (9) . Among the profiling methods available, proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy is attractive because it can provide rapid analysis of metabolites in plasma with minimal sample preparation (10 -13) using biofluids, tissue and cell extracts, and other biological source materials. For example, Saude et al (9) found that metabolic profiling of urine determined by 1 H-NMR correlated with the presence and magnitude of airway dysfunction in an asthma model using guinea pigs. Available data on metabolomics methods and results to date suggest that 1 H-NMR metabolomics analysis of human plasma may be a noninvasive diagnostic method to combine with responses to specific treatment in changing critically ill patients (14 -16) .
The present research was designed as a pilot study to evaluate metabolic effects in the ICU using 1 H-NMR spectroscopy of plasma. In this study, we investigated plasma metabolic changes in response to protocolized albumin administration in ALI patients receiving concomitant furosemide therapy (7) . We hypothesized that 1 H-NMR spectroscopy with principal component analysis (PCA) would detect differences in metabolic parameters that were not apparent in standard clinical laboratory parameters in response to albumin vs. control group responses.
MATERIALS AND METHODS
Human Subjects. This pilot study was performed on a subset of plasma samples from a randomized, controlled trial in 11 medical, surgical, and trauma ICUs within two university hospital systems, for which the details of the study design and clinical outcomes have been previously reported (7) . Briefly, mechanically ventilated hypoproteinemic patients meeting the American-European consensus definition of ALI (17) were treated with continuous infusion furosemide and randomized to receive 100 mL of either 25% human albumin or 0.9% saline intravenously every 8 hrs for a total of nine doses over 72 hrs (Fig. 1 ). This pilot study was conducted on a subset of six albumin-treated and six saline-treated patients, from whom blood samples were collected immediately before, 1 hr after, and 4 hrs after the albumin/saline administration every 8 hrs over 3 days. For example, the first, fourth, and seventh doses were the first dose of each day for 3 days. The study was reviewed and approved by the Institutional Review Boards of Emory University (Atlanta, GA) and Vanderbilt University (Nashville, TN). For a healthy group, eight subjects were recruited and studied as previously described (10) . The detailed information about participants in this study is described in Table 1 .
Sampling and Analyses. Blood samples were collected and processed and the plasma was stored as previously described (10) . Samples from ten time points were available for analysis from each patient's 7-day study period. Plasma samples were prepared, and 1 H-NMR spectra were measured at 600 MHz on a Varian INOVA 600 spectrometer (Agilent Technologies, Santa Clara, CA) under conditions where stability and reproducibility of the NMR analysis were previously established (10). Preprocessing of 1 H-NMR spectra was performed to provide baseline-corrected, aligned, and normalized spectra containing 11,708 data points as previously described (10) .
Bioinformatics and Statistics. Data dimensionality reduction by PCA was performed after the mean of each variable was centered or variance scaling was used (18 -20) to improved detection of contributions due to low-abundance metabolites using Pirouette software (Infometrix, Bothell, WA) (18) . In particular, mean-centered data are used in a way that spectral data can be given a mean of zero by subtracting the mean of spectral intensities from entries of spectral intensities at a given point (mean centering) (19) . In addition, spectral data can be scaled so that each spectral frequency has unit variance, achieved by dividing each intensity by the standard deviation of the spectral data (18) . If the data are mean centered, a chemical shift with a large intensity gets a large initial variance whereas a chemical shift with a small peak will get a small variance. Then, since PCA is a maximum variance projection method, the results are biased toward high-abundance features. In the case of plasma with these parameter settings, this biases PCA results toward lipid signals. With variance scaling, each intensity on all spectral points is preprocessed so that the each intensity becomes equally important. Therefore, variance scaling removes the dependence of the different levels of the intensities on the metabolic parameters and concentrates the relevant information into the same range for all the variables. Because the latter was more informative, all of the data presented used variance scaling except as indicated.
For PCA, 11,708 frequencies were reduced to see the metabolic profiles for the 12 subjects at each of the ten time points. Threedimensional PCA scores and loading plots with mean-centered or variance scaling were used to visualize patterns and discriminatory factors associated with albumin. Some spectral regions, which were found to contribute to separation by PCA or were known to be characteristic of known plasma metabolites (14, 16) , were analyzed by a mixed model repeated measures analysis of variance to determine the effect of albumin, time, and interaction of albumin and time. Subsequently, two-sample t tests for each frequency were used to find the significant regions that discriminated due to albumin at p Ͻ .05.
RESULTS
Subject Characteristics. The 12 patients consisted of nine females and three males, with four females and two males receiving placebo and five females and one male receiving albumin ( Table 1) . The mean age for the placebo group was 62 Ϯ 6 yrs (mean Ϯ SEM), while that for Twelve mechanically ventilated patients with acute lung injury/acute respiratory distress syndrome whose serum total protein concentrations were Ͻ6 g/dL were studied. Patients were equally randomly allocated to receive furosemide with albumin or furosemide with placebo for 72 hrs. Each patient was administered albumin or placebo every 8 hrs for a total of nine doses indicated by upward arrows. Blood samples a, b, and c were collected surrounding the first (day 1), fourth (day 2), and seventh (day 3) doses, immediately before, 1 hr after, and 4 hrs after the albumin/ placebo administration as indicated by the downward arrows. A sample was also collected in the morning on day 7, i.e., 3 days after the last dose.
the albumin group was 60 Ϯ 9 yrs. The placebo and albumin groups had similar body mass indexes (25.7 Ϯ 1.4 and 29.0 Ϯ 2.9, respectively), and each group had three patients with sepsis as the cause of ALI. For comparison of the metabolic profiles of ICU patients to those of normal individuals, data were included for fasting samples from a separate study of healthy individuals (10) . This group included three females and five males with a mean age of 54 Ϯ 10 yrs ( Table 1 ). The body mass index for this group was 27.0 Ϯ 1.1. These individuals had no known acute or chronic disease, were not on prescription medications, and were equilibrated for 3 days to a standardized diet meeting or exceeding nutritional requirements.
PCA of All Samples. To determine whether samples separated according to albumin treatment, an analysis was performed with all available 105 spectra in which samples were coded according to baseline (green), placebo (blue), or albumin (red), where the initial sample from each patient taken before the first placebo or albumin treatment was considered baseline and all samples collected after the first dose were coded as either albumin or placebo. After mean centering, 90% of the variance was represented in the first three principal components. The placebo group did not separate from the baseline samples, while there was partial separation of the albumin group from both the baseline and placebo samples in the first day ( Fig. 2A) . Data from the corresponding loading plot showed that the spectral region at 0.66 associated with the high-density lipoprotein fraction of plasma lipid contributed to the separation (data not shown).
To account for the high-abundance lipid fractions in plasma analyzed by 1 H-NMR spectroscopy with the data acquisition protocol and PCA of mean-centered data, PCA was also performed after adjustment of the variance for all of the spectral regions to enhance sensitivity for detecting contributions due to lower abundance metabolites. With varianceadjusted data, 97% of the variance was present in the first three principal components; placebo samples did not separate from baseline, while albumin samples showed almost complete separation from both baseline and placebo samples ( Fig. 2B) . Data from the loading plot showed that additional contribution to separation was present from spectral regions at 3.46 and 3.72 ppm, regions that are associated with amino acids. Consequently, the data show that 1 H-NMR spectra of plasma from albumin-treated ICU patients are largely separated in the first day from baseline and placebotreated patients and that variance scaling before analysis improves separation.
Time-Dependent Differences Due to Albumin Treatment. Analysis of data for the three sample collections on the first day of treatment showed no separation by PCA analysis (Fig. 3A) . However, by day 2, there was clear separation of samples with albumin from those without albumin (Fig. 3B) , and this was maintained on day 3 (Fig. 3C) . Data from corresponding loading plots are summarized in Table 2 . A signal at 2.89 that has been associated with the lysyl moiety of albumin contributed to separation on days 2 and 3. This signal also contributed to separation when the day 2 and 3 data were analyzed by a supervised partial least squares discriminant analysis (data not shown). As with PCA analysis, no separation was observed for day 1. Together, the data show that the three doses per day of 25 g of 25% human serum albumin are only sufficient to produce detectable changes after at least 1 day of treatment.
Analysis of corresponding loading plots ( Table 2) showed that spectral regions associated with high-density lipoprotein (0.66 ppm) and cholesterol lipid (0.91 and 0.93 ppm) contributed to separation on days 2 and 3 while low-density lipoprotein plus very low-density lipoprotein (1.25 and 1.29 ppm) also contributed to separation on day 3. Spectral regions at 0.97 and 1.02 ppm associated with valine and at 1.00 ppm associated with isoleucine also contributed to separation on days 2 and 3. A region at 1.46 ppm associated with alanine contributed to separation on day 2. Additional contributions to separation were apparent at 3.25-3.27, 3.29, 3.72, 3.74, 3.86, and 3.89 -3.90 ppm; however, these regions have extensive overlap of signals from many amino acids and glucose. In examining these data, no evidence was present for the contribution of the signal at 5.23 ppm, which is associated with glucose only, suggesting that glucose was not the feature to discriminate groups. Similarly, no evidence was present from the loading plots for contributions from signals at 2.08 and 2.09 ppm, associated with glutamine and glutamate. Thus, PCA shows that signals associated with lipids and amino acids contribute to separation of the metabolic profiles observed by 1 H-NMR spectroscopy of plasma from albumin-treated ICU patients with ALI.
Spectral Differences 3 Days After the Last Albumin Treatment. To determine whether spectral changes remained after albumin treatment, spectra were compared for day 7 and baseline (measurement on day 1 before first albumin administration). Results from unsupervised PCA showed that spectra from albumintreated patients separated from those from baseline while those from placebotreated patients did not (Fig. 4) .
Analysis of the Metabolic Trajectory Relative to Archival Spectra of Healthy Individuals. To examine whether albumin therapy improved the metabolic trajectory toward normal plasma 1 H-NMR spectra, data were compared to spectra of the 0830 time point from a previous study of eight healthy individuals (10) . Results of PCA showed that ICU patients before treatment were separated from the healthy individuals ( Fig. 5 ). Individuals treated with albumin had a time-dependent trajectory toward the healthy subjects while those receiving placebo did not (Fig. 5) .
Albumin-Dependent Variation in Selected Spectral Regions. To more specifically examine selected spectral regions for possible use to monitor metabolic changes in the ICU, regions that were discriminatory in the above analyses and regions associated with common metabolites were further studied (Fig. 6 ). Results showed that time-dependent effects were apparent in the 0.66 ppm region as measured by repeated measures analysis of variance (Fig. 6A ). Albumin-dependent effects were not significant, and t tests on individual time points showed a significant difference at only one time point on day 2. Similarly, analyses of the spectral regions associated with low-density lipoprotein and very low-density lipoprotein showed no significant effects associated with albumin treatment (Fig. 6B) . The region associated with lactate showed no significant effects with albumin ( Fig. 6C ). to baseline samples taken before the first albumin or placebo treatment. Samples were color coded green for baseline, blue for placebo, and black for albumin on day 7. Results showed that, 3 days after the last albumin treatment, metabolic differences showed a trend in patients receiving albumin. The corresponding plot for patients receiving placebo showed no separation. Data were mean centered. PC1, principal component 1; PC2, principal component 2; PC3, principal component 3. Loading plots associated with principal component analysis shown in Fig. 3 provided information with discriminatory regions of the spectra as identified by a plus sign. Where no discrimination was observed, a minus sign is indicated. There was no separation on day 1. Days 2 and 3 showed separation by principal component analysis. A contribution to separation was also observed for the spectral region from 3.25 to 3.40 ppm containing signals from many amino acids and glucose. Consequently, data were examined for contributions from glutamine, glutamate, glucose, and 1-methylhistidine, but these did not appear to contribute to separation.
Spectral regions associated with isoleucine, valine, alanine, and 1-methylhistidine showed significant differences with time and with albumin at some time points (Fig.  6, D-G) . In contrast, spectral regions associated with glutamine and glutamate did not vary significantly with time or albumin treatment (Fig. 6H) . The glucose signal did not vary significantly by time (Fig. 6I) . The signal associated with the lysyl group of albumin differed significantly due to albumin treatment only at the last time point on day 3 (Fig. 6J ).
DISCUSSION
This work is to characterize metabolic patterns that are detectable with highly accurate 1 H-NMR spectroscopy in critically ill patients and to associate these changes with a specific pharmacologic intervention (21) (22) (23) (24) . The previous work by Stringer et al (25) showed that quantitative metabolomics was considered as a useful approach for the discovery of clinically relevant biomarkers in sepsis-induced ALI. This study from which the current samples were derived showed that blood albumin levels normalized and oxygenation improved with albumin treatment compared to saline treatment (7) , consistent with the increase in albumin measured by 1 H-NMR spectroscopy. Additional analyses from that study showed an increase in protein thiol (24) , which is also consistent with the current study because albumin is the major thiol in human plasma.
Despite the reported beneficial effects of albumin treatment in hypoproteinemic ALI patients, the therapy is relatively costly and not uniformly beneficial. Thus, an individualized a priori assessment of potential benefit and the ability to monitor the biological response would improve medical care. The present study shows that, with proper development, 1 H-NMR spectroscopy may be introduced to characterize systemic metabolic responses (16) and identify patients' unique response to pharmacologic therapy and thus to optimize benefits while reducing healthcare costs (27) . These pilot data may be used to design trials that will develop algorithms using spectral patterns or selected spectral regions to optimize therapeutic efficacy by predicting the response to intervention. Furthermore, the progressive trajectory of albumin-treated patients toward a normal healthy metabolic profile suggests that the method could be of utility in the general assessment of recovery from critical illness toward normal.
The most discriminatory regions by PCA consisted of parts of the spectra in which amino acids, glucose, and other metabolites are present. While these cannot be resolved at present, the glucose signal can be corrected by measurement of glucose in other regions to enhance its predictive value. Spectral signals in other regions can be more reliably attributed to specific amino acids, such as regions associated with valine, isoleucine, alanine (possibly related to albumin catabolism to constituent amino acids), and 1-methylhistidine (a product of skeletal muscle protein breakdown). Interestingly, although the signal associated with glutamine and glutamate did not differ according to albumin treatment, the present study shows these constituents can be detected by 1 H-NMR spectroscopy. Because glutamine is an anabolic amino acid and is beneficial in select critically ill patients (28) , it is a high-interest target for application of metabolomics analysis of the inevitable nutritional imbalance of critical illness.
Commercially available flow-through NMR spectrometers are available that could be used for applications informed by this pilot study. A method using this approach has been approved by the U.S. Food and Drug Administration for measurement of blood lipids, and the present study suggests that lipid regions could be used in future studies as a means to monitor health status and progress in the ICU. Impediments to this development include proof that the metabolic profile reflects a biological response to treatment, and not simply indicates the treatment itself, and developing the early predictive potential for metabolomic profiling. Because of the limited size of this pilot study and the relatively large interindividual variations, no clinical correlations were attempted in this analysis, although the results suggest that studies should be performed using 1 H-NMR spectroscopy to test for metabolic markers of clinical outcome.
CONCLUSIONS
In summary, the present pilot study showed that 1 H-NMR spectroscopy may be useful to evaluate the effects due to albumin therapy on plasma metabolites in critically ill patients with ALI. If effective, metabolomic profiling may permit more focused trials in ALI patients, particularly with a better assessment of therapeutic effects (29) . This offers a more general benefit, which is particularly important. The most sensitive signals appear to be linked to increases in amino acid concentrations, possibly due to albumin and endogenous protein catabolism. Increased signal associated with albumin itself was detected, and changes in lipids were also present. In principle, algorithms could be developed for use with commercially available instrumentation to provide improved criteria to guide diagnostics and prognostics, a wide variety of medical treatments, and pharmacologic dosing strategies in critically ill patients.
